Celcuity, Inc. (NASDAQ:CELC) Stock Has Consensus Target Price of $154.25 According to Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $154.25.

A number of research analysts recently weighed in on the stock. Citizens Jmp reissued a “market outperform” rating and set a $177.00 price target on shares of Celcuity in a research report on Monday, August 17th. Stifel Nicolaus cut their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Wall Street Zen downgraded shares of Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. HC Wainwright reissued a “buy” rating and set a $155.00 target price on shares of Celcuity in a research report on Friday, August 14th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a report on Monday, August 17th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC purchased a new position in Celcuity during the fourth quarter worth about $310,302,000. Bank of America Corp DE bought a new stake in shares of Celcuity during the 2nd quarter valued at about $153,928,000. Wellington Management Group LLP grew its holdings in shares of Celcuity by 111.4% during the second quarter. Wellington Management Group LLP now owns 906,595 shares of the company’s stock worth $94,848,000 after purchasing an additional 477,643 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Celcuity by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock worth $82,872,000 after purchasing an additional 64,213 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC bought a new position in Celcuity in the fourth quarter valued at $35,428,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

NASDAQ CELC opened at $67.87 on Friday. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. Celcuity has a 1 year low of $45.03 and a 1 year high of $151.02. The firm has a market capitalization of $3.32 billion, a price-to-earnings ratio of -15.78 and a beta of 0.10. The firm’s 50 day simple moving average is $86.38 and its 200 day simple moving average is $101.67.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, research analysts expect that Celcuity will post -4.82 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company that develops functional diagnostic tests designed to help identify patients who may benefit from targeted cancer therapies. The company’s technology is intended to measure the activity of cellular signaling networks in living tumor cells, rather than relying solely on the presence or absence of individual biomarkers.

Celcuity’s proprietary CELsignia platform analyzes patient tumor samples to identify abnormal signaling activity associated with cancer growth and treatment response.